These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33057807)

  • 1. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
    Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
    J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
    Lane J; Langdahl B; Stone M; Kurth A; Oates M; Timoshanko J; Wang Z; Libanati C; Cosman F
    Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
    Langdahl B; Hofbauer LC; Ferrari S; Wang Z; Fahrleitner-Pammer A; Gielen E; Lakatos P; Czerwinski E; Gimeno EJ; Timoshanko J; Oates M; Libanati C
    Osteoporos Int; 2022 Dec; 33(12):2527-2536. PubMed ID: 36173415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
    McClung MR; Betah D; Deignan C; Shi Y; Timoshanko J; Cosman F
    Endocr Pract; 2023 Sep; 29(9):716-722. PubMed ID: 37406858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
    Lewiecki EM; Betah D; Humbert L; Libanati C; Oates M; Shi Y; Winzenrieth R; Ferrari S; Omura F
    J Bone Miner Res; 2024 May; 39(4):473-483. PubMed ID: 38477808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
    Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
    J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.
    Miyauchi A; Hamaya E; Nishi K; Tolman C; Shimauchi J
    J Bone Miner Metab; 2022 Jul; 40(4):677-687. PubMed ID: 35639174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F; Oates M; Betah D; Timoshanko J; Wang Z; Ferrari S; McClung MR
    J Bone Miner Res; 2024 Sep; 39(9):1268-1277. PubMed ID: 39041711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.